Spero Therapeutics Swings to Profit, FDA Decision for Tebipenem HBr Set for June 18
SPRO has more than doubled off its 52-week low of $0.505.
Summary
Spero Therapeutics reported a significant financial turnaround, achieving a net income of $8.6 million for the full year 2025, a substantial improvement from the prior year's loss, driven by increased collaboration revenue. Concurrently, the company announced a critical regulatory milestone: the FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 18, 2026, for the tebipenem HBr New Drug Application (NDA). This investigational oral antibiotic, partnered with GSK, is being developed for complicated urinary tract infections (cUTI) and previously demonstrated non-inferiority in its Phase 3 trial. The combination of strong financial performance and a definitive, near-term FDA decision date for a pivotal drug candidate is highly material for Spero Therapeutics, a small-cap biopharmaceutical company. Traders will be keenly focused on the FDA's decision in June, as approval would significantly de-risk the program and unlock potential commercial milestones and royalties.
At the time of this announcement, SPRO was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.5M. The 52-week trading range was $0.51 to $3.22. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.